comparemela.com

Page 17 - Presection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck & Co , Inc : Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (=12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

Opinion granted based on positive results from the Phase 3 KEYNOTE-716 trial If approved, KEYTRUDA would be the first anti-PD-1 immunotherapy treatment option for patients 12 years and older in

Imiquimod Cream Offers Alternative to Surgery for Vulvar Lesions

Topical imiquimod offers an alternative to surgery for women with HPV-related precancerous lesions, concludes the first head-to-head randomized trial of the two approaches.

Radiotherapy for Brain Metastases: ASTRO Updates Guidelines

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.